Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 107

Sort by

Sort Order Select

Journal Articles

This is a title in sentence case: Venetoclax-based regimens versus intensive chemotherapy in fit older adults with newly diagnosed acute myeloid leukemia (AML)：a multicenter, prospective, randomized phase II trial

Qiuyun Fang, Fei Li, Aijun Liao, Qingsong Yin, Lin Yang, Lianrong Xu, Junjie Ma, Junqing Xu, Hao Zhang, Jieyu Wang, Shaowei Qiu, Bingcheng LIU, Yingchang Mi, Jianxiang Wang, Hui Wei

Blood (2025) 146 (Supplement 1): 650.

https://doi.org/10.1182/blood-2025-650

Published: 2025

Journal Articles

Updated results of a first-in-human, Phase Ⅰa/Ⅰb study of QLS32015 (GPRC5D×CD3) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Gang An, Baijun Fang, Xiaobing Huang, Yan Xu, Fei Li, Zhen Cai, Xiaojing Yan, Xianqi Feng, Wuping Li, Xiangmin Tong, Zengjun Li, Yuzhang Liu, Feifei Che, Xin'ai Yang, Xianlin Duan, Peng Shao, Xiaoyan Kang, Lugui Qiu

Blood (2025) 146 (Supplement 1): 4049.

https://doi.org/10.1182/blood-2025-4049

Published: 2025

Journal Articles

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

Blood (2025) 146 (Supplement 1): 5812.

https://doi.org/10.1182/blood-2025-5812

Published: 2025

Journal Articles

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Zi-Xun Yan, Wenbin Qian, Ying Lu, Keshu Zhou, Dongmei Ji, Yuhua Li, Dehui Zou, Lanfang Li, Lei Zhang, Ping Li, Hongmei Jing, Chunyan Ji, Ting Niu, Fei Li, Xiaojian Zhu, Jinghua Zhao, Yu Hu, Depei Wu, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 7230.

https://doi.org/10.1182/blood-2025-7230

Published: 2025

Journal Articles

Integration of longitudinal ctdna MRD and PET/CT enhances prognostic stratification in newly diagnosed diffuse large B-cell lymphoma: A prospective multicenter study

Wei LIU, Fei Li, Keshu Zhou, Changming Dong, Zhiwei Chen, Xueli Jiao, Qianying Pan, Shunjin Zhang, Xiaoxia Wang, Xiao Liu, Dehui Zou, Lugui Qiu

Blood (2025) 146 (Supplement 1): 5323.

https://doi.org/10.1182/blood-2025-5323

Published: 2025

Journal Articles

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Blood (2025) 146 (Supplement 1): 887.

https://doi.org/10.1182/blood-2025-887

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Blood (2025) 146 (Supplement 1): 886.

https://doi.org/10.1182/blood-2025-886

Published: 2025

Journal Articles

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Blood (2025) 146 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2025-2028

Published: 2025

Journal Articles

Synergistic enhancement of APR-246 anti-leukemic activity through ENO1 inhibition in TP53- and FLT3-mutated Acute Myeloid Leukemia

Hongwei Peng, Jiaqi Wan, Xintong Yang, Jinfang Hu, Fei Li

Blood (2025) 146 (Supplement 1): 5063.

https://doi.org/10.1182/blood-2025-5063

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Blood (2025) 146 (Supplement 1): 5819.

https://doi.org/10.1182/blood-2025-5819

Published: 2025

Journal Articles

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Blood (2025) 146 (Supplement 1): 88.

https://doi.org/10.1182/blood-2025-88

Published: 2025

Journal Articles

KPNA2 enhances autophagy through activation of the non-canonical NF-κB signaling pathway, thereby promoting the induction of bortezomib resistance in multiple myeloma

Huan Wang, Fei Li

Blood (2025) 146 (Supplement 1): 7478.

https://doi.org/10.1182/blood-2025-7478

Published: 2025

Journal Articles

Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma

Blood (2025) 146 (Supplement 1): 1824.

https://doi.org/10.1182/blood-2025-1824

Published: 2025

Journal Articles

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study

Ting Niu, Lin LIU, Huijing Wu, Keshu Zhou, Wei Yang, Li Wang, Shu Cheng, Jie Wang, Jinrong Yang, Fei Li, Shiyong Zhou, Yanhong Tong, Ke Tan, Adrian Rui Liang, linyu yang, Lijuan Chen, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 5415.

https://doi.org/10.1182/blood-2025-5415

Published: 2025

Journal Articles

A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL)

Shuhua Yi, Liping Su, Bingzong Li, Zhiming Li, Zhengming Jin, Ming Jiang, Wenjuan Yu, Zengjun Li, Jun Luo, Wei Yang, Fei Li, Cailing Wang, Hui Wu, Qiang Wang, Bing Yu, Jianghua Chen, June Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 1808.

https://doi.org/10.1182/blood-2025-1808

Published: 2025

Journal Articles

Mitoxantrone hydrochloride liposome, gemcitabine, vinorelbine with or without anti-CD20 antibody (GVM±CD20) in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: A prospective, multicenter, Phase Ⅱ study

Blood (2025) 146 (Supplement 1): 1919.

https://doi.org/10.1182/blood-2025-1919

Published: 2025

Journal Articles

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

Fei Li, Stephen Opat, Dengju Li, Keshu Zhou, Peng Liu, Wei Yang, Chan Cheah, Tingyu Wang, Yu Yang, Caixia Li, Hongmei Jing, Henry Ngu, Lipeng Chen, Ting Deng, Fangjie Xie, Naisargee Shah, Zhao Xu, Richard Delarue, Jianyong Li

Blood (2025) 146 (Supplement 1): 1910.

https://doi.org/10.1182/blood-2025-1910

Published: 2025

Journal Articles

Avatrombopag improves platelet engraftment after haploidentical hematopoietic stem cell transplantation: A randomized, double-blind, multicenter, placebo-controlled trial

Blood (2025) 146 (Supplement 1): 377.

https://doi.org/10.1182/blood-2025-377

Published: 2025

Journal Articles

Insights from a multicenter study on the outcomes of liver abscess after allogeneic hematopoietic stem cell transplantation

Blood (2025) 146 (Supplement 1): 4267.

https://doi.org/10.1182/blood-2025-4267

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

This is a title in sentence case: Venetoclax-based regimens versus intensive chemotherapy in fit older adults with newly diagnosed acute myeloid leukemia (AML)：a multicenter, prospective, randomized phase II trial

Updated results of a first-in-human, Phase Ⅰa/Ⅰb study of QLS32015 (GPRC5D×CD3) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Integration of longitudinal ctdna MRD and PET/CT enhances prognostic stratification in newly diagnosed diffuse large B-cell lymphoma: A prospective multicenter study

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Synergistic enhancement of APR-246 anti-leukemic activity through ENO1 inhibition in TP53- and FLT3-mutated Acute Myeloid Leukemia

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

KPNA2 enhances autophagy through activation of the non-canonical NF-κB signaling pathway, thereby promoting the induction of bortezomib resistance in multiple myeloma

Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study

A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL)

Mitoxantrone hydrochloride liposome, gemcitabine, vinorelbine with or without anti-CD20 antibody (GVM±CD20) in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: A prospective, multicenter, Phase Ⅱ study

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

Avatrombopag improves platelet engraftment after haploidentical hematopoietic stem cell transplantation: A randomized, double-blind, multicenter, placebo-controlled trial

Insights from a multicenter study on the outcomes of liver abscess after allogeneic hematopoietic stem cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only